Search Filters

Search Results

Found 1 results

510(k) Data Aggregation

    K Number
    K011824
    Date Cleared
    2001-07-02

    (21 days)

    Product Code
    Regulation Number
    870.1025
    Why did this record match?
    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    TeleMon is indicated for use in the monitoring, recording, and alarming of multiple physiologic parameters in adult and pediatric patients to gain information for treatment, to monitor adequacy of treatment, or to exclude causes of symptoms.

    TeleMon is a prescription devices for use in healthcare facilities by trained healthcare professionals. TeleMon is not intended for home use.

    Device Description

    The Agilent M2636B TeleMon B Monitor is an upgraded version of the current M2636A TeleMon, which is an extension device for the M2600A Telemetry System. The modification in this submission is the addition of audible alarms, the display of pulse and PVC rate numerics, a software upgradeable NBP module with improved measurement time, and the addition WaveViewer functionality to the M2636A TeleMon B Monitor, a multi-parameter monitor as an extension to the M2600A Telemetry System. The new device will be known as the M2636B TeleMon B Monitor.

    AI/ML Overview

    The provided text is a 510(k) summary for the Agilent M2636B TeleMon B Monitor. It describes an upgrade to an existing device and primarily focuses on demonstrating substantial equivalence to previously cleared devices rather than providing detailed acceptance criteria or a specific study proving the device meets those criteria in the way one might find for a novel device with specific performance metrics.

    However, based on the available information, here's an attempt to extract and infer the closest information to your requested categories:

    1. A table of acceptance criteria and the reported device performance

    The document does not provide a table with specific, quantitative acceptance criteria and corresponding reported device performance values in the typical sense of a clinical or performance study.

    Instead, the acceptance criteria are implicitly tied to the performance specifications of the predicate devices. The document states:

    "Pass/fail criteria are based on the specifications cleared for the predicate devices to demonstrate substantial equivalence."

    This implies that the M2636B TeleMon B Monitor is expected to perform at least as well as, or within the accepted specifications of, the legally marketed predicate devices, particularly the M2636A TeleMon Monitor.

    The "reported device performance" is not explicitly quantified but is implicitly stated to be in compliance with the predicate device's performance through the substantial equivalence argument. The modifications (audible alarms, display of pulse and PVC rate numerics, improved NBP module, WaveViewer functionality) are presented as additions/improvements, not as changes to core performance that would necessitate new, specific performance studies beyond ensuring they integrate safely and effectively within the existing framework.

    2. Sample size used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective)

    The document does not specify a "test set" in the context of a clinical study with a sample size. The testing activities mentioned are primarily related to design controls, system-level tests, integration tests, safety tests, interference testing, and hardware testing. These are typically engineering verification and validation activities, not clinical trials with patient data.

    Therefore, there is no information on:

    • Sample size used for a test set.
    • Data provenance (country of origin, retrospective/prospective).

    3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts

    Not applicable, as no clinical "test set" requiring expert-established ground truth is described in the provided text. The submission focuses on substantial equivalence based on engineering and performance specifications relative to predicate devices.

    4. Adjudication method (e.g. 2+1, 3+1, none) for the test set

    Not applicable, as no clinical "test set" requiring adjudication for ground truth is described.

    5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

    Not applicable. This device is a multi-parameter patient monitor, not an AI-assisted diagnostic tool that would involve human readers or an MRMC study to assess diagnostic improvement.

    6. If a standalone (i.e. algorithm only, without human-in-the-loop performance) was done

    Not applicable. This device is not an algorithm for medical image analysis or a similar application where standalone algorithm performance would be assessed in isolation. It is a monitoring device that presents physiological data to healthcare professionals.

    7. The type of ground truth used (expert consensus, pathology, outcomes data, etc)

    Not applicable, as there is no mention of a study involving ground truth in the context of clinical performance data. The "ground truth" for this device's performance would be its accurate measurement and display of physiological parameters as defined by its technical specifications and comparison to established medical standards (e.g., accuracy of ECG, NBP measurements) which are implicitly covered by its predicate devices.

    8. The sample size for the training set

    Not applicable. The document does not describe any machine learning or AI components that would require a "training set."

    9. How the ground truth for the training set was established

    Not applicable. As no training set is described, there is no information on how its ground truth would be established.


    Summary of Study (as described in the 510(k) context):

    The "study" described in this 510(k) is primarily focused on design controls, verification, validation, and testing activities to ensure the new M2636B TeleMon B Monitor meets the safety, performance, and reliability characteristics established for its predicate devices.

    The key statement regarding this "study" is:

    "Verification, validation, and testing activities will be successfully conducted prior to commercialization to establish the safety, performance, and reliability characteristics of the M2636B TeleMon B Monitor. Testing involves system level tests, integration tests, safety tests from hazard analysis, interference testing, and hardware testing. Pass/fail criteria are based on the specifications cleared for the predicate devices to demonstrate substantial equivalence."

    This indicates an engineering and regulatory compliance approach to demonstrating equivalence, rather than a clinical trial with specific patient-based performance metrics against a clinical ground truth. The acceptance is based on meeting the established specifications of the M2636A TeleMon Monitor (K001436) and other predicate devices in terms of functionality and safety.

    Ask a Question

    Ask a specific question about this device

    Page 1 of 1